Luma Pediatrics

Pediatric Pulse · Daily source check

What current public-health signals relevant to North Texas show.

A morning snapshot of air quality, pollen, respiratory hospitalizations, laboratory surveillance, provisional disease reports, and pediatric medication signals. Each section identifies the geography it actually represents.

Checked Sunday, Sep 27 · 4:52 PM CT · source reporting schedules vary

Today at a glance

Elevated clinic readiness: pollen and respiratory illness signals active

High readiness

Air quality is currently moderate (AQI 53) for Dallas-Fort Worth. Tree pollen is very high and grass pollen is high. Regional respiratory illness activity is trending up, so the clinic may see more cough, congestion, wheezing, and fever-related calls. Some pediatric medications remain limited or in shortage; verify availability before sending high-volume prescriptions. Consider keeping allergy, asthma, and same-day sick visit workflows ready.

Tree pollen is very high (Elm, Ragweed, Grasses dominant).
AQI is 53 (Moderate).
Regional RSV activity is rising (current level unknown).
Flu activity is rising (current level unknown).
Combined respiratory hospitalization rate is rising in Texas DSHS PHR 2/3 (1.9 per 100,000).
2 pediatric-relevant medication(s) flagged as limited or in shortage.
Community virus watch: Influenza, COVID-19, Rhinovirus / Enterovirus (+1 more) elevated or rising regionally.
Snapshot Sep 27, 2026 · 4:52 PM Refreshed Sep 27, 2026 · 4:52 PM Coverage: 75071, 75069, 75070, 75072 +6 more

Do this today

Operational playbook

  • Keep allergy and asthma guidance ready for cough, congestion, and wheeze-related calls.
  • Hold a few same-day sick visit slots and prepare a fever/cough triage script for front desk and MAs.
  • Check pharmacy availability before prescribing constrained medications and prepare alternative regimens.
  • Hold a few same-day sick visit slots if call volume rises this week.
  • Keep allergy and asthma guidance materials ready for families calling about cough or wheeze.
  • Reinforce asthma action plan use during visits for wheezing or asthma-history patients.

Built for provider, MA, and front-desk triage decisions — not a diagnosis tool.

Air quality

Source: EPA AirNow

Dallas-Fort Worth

53Moderate

Primary pollutant: PM2.5

Available forecast

Sun
—
Unhealthy for Sensitive Groups
Mon
—
Moderate
Tue
—
Good

Air quality is in the Moderate range. Sensitive patients may notice mild symptoms.

Observation date: 2026-09-27

Pollen

Source: Google Pollen API

Tree
Very High
Grass
High
Weed
Very High

Dominant allergens: Elm, Ragweed, Grasses

Pollen is very high (Elm, Ragweed, Grasses prominent). Expect more allergy-symptom and wheezing-related calls.

Respiratory hospitalization activity

Source: Texas DSHS respiratory hospitalization surveillance

Texas DSHS Public Health Region 2/3
RSV
0.2per 100k
Rising
Influenza
0.5per 100k
Rising
COVID-19
1.2per 100k
Stable
Combined admission rate
1.9 per 100k · Rising
Reporting week
2026-09-19

PHR 2/3 hospitalization signals: RSV rising, flu rising, combined hospital admission rate rising. Rates are weekly new laboratory-confirmed admissions per 100,000.

These are hospitalization rates for the full Texas DSHS Public Health Region 2/3, not McKinney or Collin County counts.

Community virus watch

Source: CDC NREVSS and CDC national respiratory laboratory surveillance

Texas, HHS Region 6, and United States; see each cardStale since Sep 18, 2026

Respiratory viruses

RSV
0.7% positive - stable

CDC NREVSS, Texas, week ending 2026-09-19: 0.7% of reported tests were positive.

CDC NREVSS · Texas · 2026-09-19

Influenza
2.7% positive - rising

CDC national respiratory laboratory surveillance, United States, week ending 2026-09-19: 2.7% of reported tests were positive.

CDC national respiratory laboratory surveillance · United States · 2026-09-19

COVID-19
9.7% positive - easing

CDC NREVSS, Texas, week ending 2026-09-19: 9.7% of reported tests were positive.

CDC NREVSS · Texas · 2026-09-19

Rhinovirus / Enterovirus
33.1% positive - stable

CDC NREVSS, HHS Region 6 (AR, LA, NM, OK, TX), week ending 2026-09-19: 33.1% of reported tests were positive.

CDC NREVSS · HHS Region 6 (AR, LA, NM, OK, TX) · 2026-09-19

Human Metapneumovirus (hMPV)
0.6% positive - stable

CDC NREVSS, HHS Region 6 (AR, LA, NM, OK, TX), week ending 2026-09-19: 0.6% of reported tests were positive.

CDC NREVSS · HHS Region 6 (AR, LA, NM, OK, TX) · 2026-09-19

Parainfluenza
0.8% positive - stable

CDC NREVSS, HHS Region 6 (AR, LA, NM, OK, TX), week ending 2026-09-19: 0.8% of reported tests were positive.

CDC NREVSS · HHS Region 6 (AR, LA, NM, OK, TX) · 2026-09-19

Adenovirus
5.4% positive - rising

CDC NREVSS, HHS Region 6 (AR, LA, NM, OK, TX), week ending 2026-09-19: 5.4% of reported tests were positive.

CDC NREVSS · HHS Region 6 (AR, LA, NM, OK, TX) · 2026-09-19

Gastrointestinal viruses

Norovirus
4.9% positive (centered 3-week average) - stable

CDC NREVSS, Southern U.S. Census Region, centered three-week average ending 2026-08-29: 4.9% positive. CDC displayed 854 tests for the specified week; dashboard updated 2026-09-04.

CDC NREVSS (controlled weekly import) · Southern U.S. Census Region · 2026-08-29 · showing last-known-good value

Rotavirus
3.2% positive (centered 3-week average) - rising

CDC NREVSS, Southern U.S. Census Region, centered three-week average ending 2026-08-29: 3.2% positive. CDC displayed 791 tests for the specified week; dashboard updated 2026-09-04.

CDC NREVSS (controlled weekly import) · Southern U.S. Census Region · 2026-08-29 · showing last-known-good value

Other common pediatric viral illnesses

Hand, Foot & Mouth Disease
Seasonal watch

Seasonal watch only. Do not infer a local outbreak without an official Texas DSHS or local health department notice.

CDC and Texas DSHS guidance · Seasonal context; not a local activity estimate

Fifth Disease (Parvovirus B19)
Local surveillance limited

Parvovirus B19 is not nationally notifiable and has no routine U.S. surveillance feed. Use official health advisories only when issued.

CDC · No routine local surveillance

Each quantitative value identifies its source geography and reporting week. Non-quantitative cards do not imply current local activity.

Quantitative cards use laboratory test positivity. The display bands are Luma-defined summaries, not CDC risk levels. Geography varies by card.

Vaccine-preventable disease watch

Source: CDC NNDSS Weekly Data (Texas)

Measles
Texas (state-level, YTD through MMWR week 37)
Reported cases
YTD cases: 178 (vs 803 same period last year)

178 provisional Texas cases YTD vs 803 in the same period last year. An official advisory is required to label an outbreak.

Vaccine relevance: MMR-preventable. Highly contagious; airborne. Confirm MMR1 (12-15 mo) and MMR2 (4-6 yr) at every visit.

Suggested action: Verify MMR status, prompt catch-up doses, and review measles isolation/notification protocol with staff.

Pertussis (whooping cough)
Texas (state-level, YTD through MMWR week 37)
Reported cases
YTD cases: 183 (vs 3159 same period last year)

183 provisional Texas cases YTD vs 3159 in the same period last year. An official advisory is required to label an outbreak.

Vaccine relevance: DTaP/Tdap-preventable. Infants under 2 mo are highest-risk. Confirm caregiver Tdap (cocooning).

Suggested action: Low threshold for testing prolonged paroxysmal cough; confirm DTaP series and Tdap for adolescents.

Hepatitis A
Texas (state-level, YTD through MMWR week 37)
Reported cases
YTD cases: 39 (vs 72 same period last year)

39 provisional Texas cases YTD vs 72 in the same period last year. An official advisory is required to label an outbreak.

Vaccine relevance: HepA-preventable. Two-dose series starting at 12 mo.

Suggested action: Confirm HepA series at well visits; emphasize for travel to endemic regions.

Varicella (chickenpox)
Texas (state-level, YTD through MMWR week 37)
Reported cases
YTD cases: 301 (vs 362 same period last year)

301 provisional Texas cases YTD vs 362 in the same period last year. An official advisory is required to label an outbreak.

Vaccine relevance: Varicella-preventable. Two-dose series (12-15 mo, 4-6 yr).

Suggested action: Confirm two-dose varicella status at school-age visits; counsel on rash isolation.

Mumps
Texas (state-level, YTD through MMWR week 37)
Reported cases
YTD cases: 8 (vs 26 same period last year)

8 provisional Texas cases YTD vs 26 in the same period last year. An official advisory is required to label an outbreak.

Vaccine relevance: MMR-preventable. Outbreaks often occur in close-contact settings (camps, schools).

Suggested action: Confirm MMR2 in school-age and adolescents; review parotitis differential during outbreaks.

Invasive pneumococcal disease (age <5)
Texas (state-level, YTD through MMWR week 37)
Reported cases
YTD cases: 53 (vs 58 same period last year)

53 provisional Texas cases YTD vs 58 in the same period last year. An official advisory is required to label an outbreak.

Vaccine relevance: PCV15/PCV20-preventable. Series at 2, 4, 6, 12-15 mo.

Suggested action: Confirm PCV series; review post-splenectomy and high-risk indications.

These are provisional Texas case reports, not local case counts or official outbreak determinations. Consult CDC, Texas DSHS, or the local health department for confirmed outbreak notices.

Methodology: Labels compare current-year provisional Texas totals with the same MMWR week in the prior year. They do not infer epidemiologic linkage or declare an outbreak.

Pediatric medication watchlist

Source: FDA Drug Shortages / openFDA

Amoxicillin (suspension)
Antibiotic
Unknown

Pediatric relevance: First-line for AOM, strep pharyngitis, CAP in many pediatric patients.

Not listed in FDA's current or resolved shortage records; this does not confirm local availability.

Suggested action: Confirm pharmacy availability before prescribing high-volume liquid formulations; consider alternative concentrations.

Amoxicillin-clavulanate (suspension)
Antibiotic
Unknown

Pediatric relevance: Common second-line for AOM and sinusitis when amoxicillin is insufficient.

Not listed in FDA's current or resolved shortage records; this does not confirm local availability.

Suggested action: Verify availability with local pharmacy before sending; have alternate regimens ready.

Cefdinir (suspension)
Antibiotic
Unknown

Pediatric relevance: Common penicillin alternative for AOM and sinusitis.

Not listed in FDA's current or resolved shortage records; this does not confirm local availability.

Suggested action: Monitor for changes if amoxicillin demand surges.

Albuterol HFA inhaler
Bronchodilator
Unknown

Pediatric relevance: Core rescue therapy for pediatric asthma and reactive airway disease.

Not listed in FDA's current or resolved shortage records; this does not confirm local availability.

Suggested action: Reinforce spacer use and asthma action plans; remind families to refill before respiratory season peaks.

Albuterol nebulizer solution
Bronchodilator
Resolved

Pediatric relevance: Used for in-clinic nebulizer treatments and home neb therapy in younger children.

FDA records found, with no current shortage entries.

Suggested action: Track on-hand clinic stock; prefer MDI + spacer when clinically appropriate.

Oseltamivir (suspension)
Antiviral
Unknown

Pediatric relevance: Influenza treatment in eligible pediatric patients during flu season.

Not listed in FDA's current or resolved shortage records; this does not confirm local availability.

Suggested action: Revisit if regional flu activity rises.

Methylphenidate
ADHD stimulant
Shortage

Pediatric relevance: Common ADHD therapy; shortages affect refill workflows and family planning.

38 current FDA presentation record(s); 4 unavailable and 11 limited. Local pharmacy supply may differ.

Suggested action: Discuss formulation alternatives with family; coordinate with pharmacy before changing dose or product.

Amphetamine / dextroamphetamine
ADHD stimulant
Shortage

Pediatric relevance: Alternate ADHD therapy; shortages affect refill and switching options.

73 current FDA presentation record(s); 19 unavailable and 10 limited. Local pharmacy supply may differ.

Suggested action: Plan refill timing carefully; consider documented alternative regimens per family.

FDA status is national and presentation-specific, not local pharmacy inventory. "Unknown" means the product was not listed in the queried FDA records; it does not confirm availability.

Sources & disclaimer

Data sources

  • EPA AirNow (air quality)
  • Google Pollen API (modeled tree, grass, and weed forecast near McKinney)
  • Texas DSHS Public Health Region 2/3 (respiratory hospitalization rates)
  • CDC NREVSS and CDC national respiratory laboratory surveillance
  • FDA Drug Shortages / openFDA (national product status)
  • CDC NNDSS Weekly Data (Texas provisional counts)

Data checked daily; source reporting schedules vary. Each quantitative signal retains its source geography and reporting date.

Internal operational dashboard for Luma Pediatrics. Public health data is used for awareness and planning only. Clinical decisions should be based on provider judgment and patient-specific evaluation. Do not use this dashboard as a diagnosis tool.